Chufan Wang

ORCID: 0000-0002-6029-7366
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Immunotherapy and Immune Responses
  • Virus-based gene therapy research
  • Hepatitis B Virus Studies
  • RNA Interference and Gene Delivery
  • Immune cells in cancer
  • Cancer Immunotherapy and Biomarkers
  • Advanced Nanomaterials in Catalysis
  • Bacteriophages and microbial interactions
  • CAR-T cell therapy research
  • Phagocytosis and Immune Regulation
  • Nanoparticles: synthesis and applications
  • Advancements in Transdermal Drug Delivery
  • Aortic aneurysm repair treatments
  • Nanocluster Synthesis and Applications

Xiamen University
2020-2024

Abdominal aortic aneurysm (AAA) is a highly lethal cardiovascular disease that currently lacks effective pharmacological treatment given the complex pathophysiology of disease. Here, single-cell RNA-sequencing data from patients with AAA and mouse model are analyzed, which reveals pivotal pathological changes, including M1-like polarization macrophages loss contractile function in smooth muscle cells (SMCs). Both cell types express integrin αvβ3, allowing for their dual targeting single...

10.1002/adma.202405761 article EN Advanced Materials 2024-06-24

ConspectusWith a plethora of advances in nanotechnology and biotechnology, the development natural particle-based drug delivery vectors is rapidly emerging field; these are highly optimized for specific functions vivo, have features typically required vectors, even possess more efficient mechanisms compared to synthetic such as selective targeting extended circulation time. Virus-like particles (VLPs) virus-derived nanoparticles composed one or different protein subunits precise manner with...

10.1021/accountsmr.3c00050 article EN Accounts of Materials Research 2023-08-25

Tumor cells are rich in antigens, which provide a reliable antigen library for the design of personalized vaccines. However, an effective tumor vaccine vector that can efficiently deliver antigens to lymphoid organs stimulate strong CD8+ cytotoxic T-lymphocyte immune response is still lacking. Here we designed dual-antigen delivery system based on hepatitis B virus core virus-like particles (HBc VLPs). We first confirmed different antigen-loaded HBc VLP monomers could be assembled into...

10.1021/acsami.0c16012 article EN ACS Applied Materials & Interfaces 2020-11-18

Advanced antibacterial methods are urgently needed to deal with possible infectious diseases. As promising alternatives antibiotics, enzyme-mimic nanocatalysts face bottlenecks of low activities and indistinct catalytic mechanisms, which seriously restrict their development for anti-infection treatment. Herein, metastable copper sulfide (Cu2-xS) nanozymes diversiform sizes compositions were selected adjust the electronic structure enhancing activities. The as-synthesized large thin...

10.1021/acsami.1c17985 article EN ACS Applied Materials & Interfaces 2021-11-02

The tumor microenvironment typically possesses immunosuppressive properties that hinder the effectiveness of antitumor immune responses, even in context immunotherapies. However, it is observed pathogenic microorganisms can trigger strong responses during infection, offering a potential means to counteract environment tumors. In this study, protein nanocage called CpG@HBc nanocages (NCs) developed, which mimics structure hepatitis B virus and combines with an immunostimulatory component...

10.1002/smll.202301281 article EN Small 2023-06-07

Abstract Therapeutic cancer vaccines have the potential to induce regression of established tumors, eradicate microscopic residual lesions, and prevent metastasis recurrence, but their efficacy is limited by low antigenicity soluble antigens immunosuppressive tumor‐associated macrophages (TAMs) that promote tumor growth. In this study, a novel strategy reported for overcoming these defenses: dual‐targeting nano‐vaccine (NV) based on hepatitis B core antigen (HBcAg) derived virus‐like...

10.1002/adhm.202401416 article EN Advanced Healthcare Materials 2024-06-07
Coming Soon ...